Bretazenil

Varför har inte vi dessa preparat i Sverige, bra vid problematiskt bruk Bensodiazepiner och Zoplikon, Zolpidem? Det är inte nya läkemedel. Dessutom mycket bra partiella agonister

Bretazenil

Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine[1] anxiolytic drug which is derived from the benzodiazepine family, and was invented in 1988.

It is most closely related in structure to the GABA antagonist flumazenil, although its effects are somewhat different.

It is classified as a high-potency benzodiazepine due to its high affinity binding to benzodiazepine binding sites[2][3] where it acts as a partial agonist.[4]

Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile.[

5] In particular bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome.

[6] Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5 and α6 subunit containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5 GABAA benzodiazepine receptor complexes.[1]

Bretazenil

Home » Topics » Addiction

Publish DateJanuary 25, 2019Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment RetentionHannah Dellabel

Share by Email

The use of benzodiazepine, only if prescribed, may not affect retention of methadone medication-assisted treatment, according to a study published in the Journal of Addiction Medicine.

AdvertisementThe study included patients from 52 opioid use disorder outpatient clinics who were initiating methadone medication-assisted treatment and taking prescribed benzodiazepines, nonprescribed benzodiazepines, or no benzodiazepines.

Participants were followed from treatment initiation to treatment discontinuation, death, or 1-year follow-up.

Urine drug screening (UDS) data and prescribing information from single-payer health records were examined. Advertiseme

The study’s primary outcome was methadone treatment retention at the 1-year follow-up. A total of 3692 participants initiating methadone-assisted treatment for the first time were included in the study.

Of these, 76% had no benzodiazepine prescription and <30% screening positive for benzodiazepine, 13% had a benzodiazepine prescription but had negative UDS, 6% did not have a benzodiazepine prescription but had positive UDS, and 6% had a benzodiazepine prescription and had positive UDS.Advertisement

Today’s Top Picks for You on Psychiatry Advisor

Little Evidence for the Long-Term Efficacy of Sleep Medication Among Women in MidlifeOpioid Dose, Treatment Length Linked to Adverse Health Care Events and OutcomesA Screening Program for Unhealthy Alcohol Use Integrated Into Electronic Health Record Software Feasible and Effective

CONTINUE READING

Patients using nonprescribed benzodiazepine who had positive UDS were found to be more likely to discontinue methadone treatment (adjusted odds ratio, 0.38; 95% CI, 0.27-0.53) compared with participants not using benzodiazepine or those using benzodiazepine as prescribed.

“Importantly, we urge both the physician and patient to seek alternative clinical options to [benzodiazepine] prescribing, due to the potential for developing physical dependence (and [benzodiazepine] use disorder) to [benzodiazepine] and the risks [for] negative interactions with opioids,” noted the study’s authors.

Reference

Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC.

Evaluating the impact of prescribed versus nonprescribed benzodiazepine use in methadone maintenance therapy: results from a population-based retrospective cohort study.

[published online December 12, 2018]. J Addict Med. doi:10.1097/ADM.0000000000000476

This article originally appeared on Clinical Pain Advisor



Brelazil

Advanced Title & authors Abstract Similar articles Cited by Publication types MeSH terms Substances Related information LinkOut - more resources ReviewPartial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disordersW Haefely et al.

Adv Biochem Psychopharmacol. 1992.Show details Abstract PubMed PMID CiteAbstract

The classic benzodiazepines produce anxiolytic, anticonvulsant, sedative and myorelaxant effects at overlapping dose ranges.

Efforts to reduce the sedative/myorelaxant component of this profile has a long history. Two rational approaches might theoretically lead to the desired drugs.

One is based on the combination of partial (low efficacy) agonists of the benzodiazepine receptor with different receptor reserves in neurons subversing various functions.

The other approach is based on the existence of GABAA-benzodiazepine receptor polymorphism and assumes that distinct receptor variants may be more prevalent on neurons involved in various

CNS functions. Results are presented that were obtained with the partial agonist bretazenil and three other ligands in vitro as well as in vivo.

Curves relating fractional receptor occupancy and various effects (potentiation of GABA-induced chloride flux, anticonvulsant, anticonflict and sedative effects) are fully consistent with the view that the particular profile of activity of bretazenil is the result of partial agonism.

Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order.

Clinical aspects of partial benzodiazepine receptor agonists are discussed on the basis of the preliminary information available to date.

Likes

Comments